(Reuters) -Eli Lilly said on Thursday its experimental drug met the main goals of a late-stage study to test it as a treatment for moderately to severely active Crohn’s disease, a type of inflammatory bowel disease.
In the study, 54.1% patients achieved clinical remission when treated with the drug, mirikizumab, after 52 weeks, compared with 19.6% who received placebo.
Lilly said it plans to submit data from the late-stage study in 2024 to the U.S. Food and Drug Administration as part of its marketing application, as well as other global health regulators.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Arun Koyyur and Sriraj Kalluvila)
